Experimental car-t cell therapy for relapsed b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have B-cell lymphoma that did not respond to or came back after at least two prior treatments, including one with a CD20-targeting drug like rituximab.
- Your lymphoma cells must have a protein called CD19 on their surface (this will be checked on a tumor sample or blood test).
- You must have at least one tumor that can be measured on a scan.
- Your overall health must be good enough to undergo the treatment, with adequate organ function and an expected survival of more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Hear when a new Non-hodgkin Lymphoma,B Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.